Voya Investment Management LLC Savara Inc Transaction History

Voya Investment Management LLC

  • $79.9 Billion
  • Q3 2024

A detailed history of Voya Investment Management LLC transactions in Savara Inc stock. As of the latest transaction made, Voya Investment Management LLC holds 83,451 shares of SVRA stock, worth $276,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,451
Previous 83,474 0.03%
Holding current value
$276,222
Previous $336,000 5.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.96 - $5.07 $91 - $116
-23 Reduced 0.03%
83,451 $353,000
Q2 2024

Dec 03, 2024
BUY
$3.66 - $5.34 $84 - $122
23 Added 0.03%
83,474 $336,000
Q2 2024

Aug 14, 2024
SELL
$3.66 - $5.34 $5,808 - $8,474
-1,587 Reduced 1.87%
83,474 $336,000
Q1 2024

May 15, 2024
BUY
$4.19 - $5.59 $199,506 - $266,167
47,615 Added 127.16%
85,061 $423,000
Q3 2023

Nov 14, 2023
BUY
$2.97 - $3.88 $15,966 - $20,858
5,376 Added 16.76%
37,446 $141,000
Q2 2023

Aug 14, 2023
BUY
$1.69 - $3.24 $54,198 - $103,906
32,070 New
32,070 $102,000
Q2 2021

Aug 16, 2021
SELL
$1.51 - $2.29 $39,809 - $60,373
-26,364 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$1.0 - $1.47 $9,803 - $14,410
9,803 Added 59.19%
26,364 $30,000
Q2 2020

Aug 14, 2020
SELL
$1.8 - $3.05 $3,999 - $6,777
-2,222 Reduced 11.83%
16,561 $41,000
Q1 2020

May 15, 2020
SELL
$1.91 - $4.08 $7,659 - $16,360
-4,010 Reduced 17.59%
18,783 $40,000
Q4 2019

Feb 14, 2020
BUY
$0.71 - $4.91 $8,461 - $58,517
11,918 Added 109.59%
22,793 $102,000
Q3 2018

Nov 14, 2018
BUY
$10.49 - $12.87 $114,078 - $139,961
10,875 New
10,875 $121,000

Others Institutions Holding SVRA

# of Institutions
129
Shares Held
158M
Call Options Held
67.6K
Put Options Held
29.4K
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $377M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email